Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

(2012) William D Chey et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

(2012) Satish Rao et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design

(2010) Ann Marie Trentacosti et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

(2010) Robert W. Busby et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

(2010) Alexander P. Bryant et al.   LIFE SCIENCES

Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report

(2009) Brennan Spiegel et al.   GASTROENTEROLOGY

Three ways to quantify uncertainty in individually applied “minimally important change” values

(2009) Henrica C.W. de Vet et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain

(2009) h. eutamene et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Irritable Bowel Syndrome

(2008) Emeran A. Mayer   NEW ENGLAND JOURNAL OF MEDICINE